SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant selling pressure after Marvell canceled all existing purchase orders, citing a breach of confidentiality obligations following public disclosures by company management. The community is actively debating whether this is a structural failure for the company's optics technology or an orchestrated exit by Marvell to favor internal alternatives, with many investors calling for immediate management accountability.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is experiencing extreme volatility and rapid price movement driven by its tiny float and heavy speculative trading. Community sentiment is deeply divided, with many traders focused on short squeeze potential and aggressive momentum setups, while others caution against the stock's history of erratic swings and potential dilution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it breaks into fresh all-time high territory, with investors aggressively debating its massive valuation and momentum-driven rally. The community is focused on the stock's role as the central infrastructure play in the AI supercycle, with many traders aggressively targeting further upside while skeptics remain wary of the rapid technical expansion.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid investor excitement over a proposed $835 million acquisition of European Lithium, which would consolidate full control of the Tanbreez rare earth project and bolster the company's cash position. The community is actively discussing the potential for a short squeeze and speculating on long-term growth driven by domestic mineral supply security, with many users highlighting the stock's role in defense-related supply chains.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to the company's Q1 financial results, which show the first significant revenue growth in 19 quarters alongside improved profitability and a leaner operating model. While some community members remain skeptical of the turnaround and continue to highlight past volatility, others are debating the potential for a short squeeze fueled by significant short interest and the company's ongoing pivot toward its "Everything Home" ecosystem.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors digest news of a significant potential contract with the Pentagon to deploy Gemini models in classified settings, occurring alongside reports of custom chip development efforts in collaboration with Marvell. While bulls highlight Alphabet's strong cloud growth and ongoing AI infrastructure expansion, the stock faces lingering sentiment headwinds from EU antitrust scrutiny regarding data sharing requirements.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently the center of community discussion following its historic first-ever point-to-point eVTOL demonstration flights in New York City, sparking intense debate between long-term investors highlighting this milestone and traders debating the stock's short-term volatility and institutional short interest. While proponents point to successful testing and robust partnerships as evidence of a leading position in the urban air mobility sector, others remain focused on the stock's recent price consolidation and the broader risks associated with the pre-revenue industry.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing extreme volatility and intense community debate, as traders weigh massive short-term swings driven by momentum against concerns that the stock is a speculative pump-and-dump scheme. The community is actively tracking low-float dynamics and aggressive short-squeeze attempts while debating the sustainability of recent rallies.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is experiencing significant market volatility as investors weigh a double-beat earnings report and raised forward guidance against broader AI sector fatigue and concerns regarding customer concentration. The community is actively debating whether the recent price pullbacks represent a strategic buying opportunity for a key AI infrastructure player or a deeper correction driven by valuation concerns and shifting institutional sentiment.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investor interest surges over a significant spike in short borrow fees and active discussions surrounding a potential short squeeze fueled by thin liquidity and mounting pressure on short sellers. The community is heavily focused on the company's expansion into AI cloud services via the Northern Data acquisition and strong strategic backing from Tether.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.&nbsp;</li><li>The patient experienced only low-grade treatment-emergent adverse effects and continued treatment.</li><li>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments.</li></ul>Shares of Aprea Therapeutics, Inc. (APRE) rallied 15% on Wednesday after the company said that it observed tumor shrinkage in a patient enrolled in an early-stage trial of its experimental drug APR-1051.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-additional-positive-clinical">reported</a> a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, Aprea said. The first patient to achieve a partial response at 150 mg dose levels also remains on therapy as the experimental oral therapy is generally well-tolerated, the company added.<h2 class="st-heading-2">Steps Ahead</h2>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments. Further updates from the trial are expected in the second quarter of 2026. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors and nearly 22 patients have been treated at varying doses of 10mg to 220 mg.“We believe the magnitude of tumor reduction and the substantial drop in CA-125 in this patient provides further evidence of APR-1051’s biologic activity and potential therapeutic impact,” said Eugene Kennedy, Chief Medical Advisor at Aprea.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around APRE stock increased from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘normal’ levels.According to data from Koyfin, all the three analysts covering the stock rate it ‘Buy’ or higher. The 12-month average price target on the stock is at $5.33, representing a potential upside of about 788% from last day’s closing price.<a href="https://stocktwits.com/symbol/APRE">APRE stock</a> has declined 80% over the past 12 months.&nbsp;Read More: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy">SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aprea Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Current Price	$0.8611
Prev Close	$0.9299
Open	$0.952
Dividend Yield	0.00%
50-Day Moving Average	$0.80
Beta	0.73
Avg. Volume	552,075.31
PE Ratio	-0.47

52-Week High	$2.22
52-Week Low	$0.548
Market Capitalization	$11.51M
EPS (Annual)	-$1.93
Price to Book	0.61
Revenue Per Employee	$35,719.88

APRE
Aprea Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APRE News

APREAprea Therapeutics Inc